

**EU-RISK MANAGEMENT PLAN FOR GENERICS - PART VI**

**MEROCARB**

**RMP Version number: 2.0**

**Date of final sign off: 29.09.2020**

**COMPANY: Antibiotice SA**

**QPPV Name: MIHAELA MOSNEGUTU**

**Telephone number: +40 232 209 256**

**E-mail address: mihaela.mosnegutu@antibiotice.ro**

## Part VI: Summary of the risk management plan for Merocarb powder for solution for injection/infusion

This is a summary of the risk management plan (RMP) for Merocarb powder for solution for injection/infusion. The RMP details important risks of Merocarb powder for solution for injection/infusion, how these risks can be minimised, and uncertainties (missing information).

Merocarb powder for solution for injection/infusion Summary of product characteristics (SmPC) and its package leaflet (PL) give essential information to healthcare professionals and patients on how the drugs should be used.

### I. The medicine and what it is used for

Merocarb powder for solution for injection/infusion is indicated for the treatment of:

- Severe pneumonia, including hospital and ventilator-associated pneumonia;
- Broncho-pulmonary infections in cystic fibrosis;
- Complicated urinary tract infections;
- Complicated intra-abdominal infections;
- Intra- and post-partum infections;
- Complicated skin and soft tissue infections;
- Acute bacterial meningitis;
- Neutropenic patients with fever.

### II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Merocarb powder for solution for injection/infusion, together with measures to minimise such risks, are outlined below.

Measures to minimise the risks identified: none.

No additional risk minimisation measures are proposed.

In addition to these measures, routine pharmacovigilance activities including adverse reactions reporting, PSUR, medical literature monitoring, and other activities as required under EU legislation, are made.

If important information that may affect the safe use of Merocarb powder for solution for injection/infusion is not yet available, it will be list under missing information.

#### II. A. List of important risks and missing information

Important risks of Merocarb powder for solution for injection/infusion are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Merocarb powder for solution for injection/infusion. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected.

Summary of safety concern	
Important identified risks	None
Important potential risks	None
Missing information	None

## **II. B. Summary of important risks**

The safety information in the proposed Product Information is aligned to the reference medicinal product and with the comments from Summary of assessment per safety concerns from the HaRP Assessment Report of meropenem dated 29 April 2020 published by CMDh.

## **II. C. Post- authorisation development plan**

### **II.C.1 Studies which are conditions of the marketing authorisation**

Not applicable

### **II.C.2 Other studies in post-authorisation development plan**

Not applicable